Neoplasms, Colorectal Completed Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Colorectal Neoplasms / Colorectal Neoplasm / Neoplasms,Colorectal

IndicationStatusPhase
DBCOND0036298 (Neoplasms, Colorectal)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02246049A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRCTreatment
NCT01722162Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal CancerTreatment
NCT00615056A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line RegimenTreatment
NCT00904839BIBF 1120 Versus Bevacizumab in Metastatic Colorectal CancerTreatment
NCT01677884Intra-arterial Hepatic Bevacizumab and Systemic ChemotherapyTreatment
NCT01765582A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Participants With Metastatic Colorectal Cancer (STEAM)Treatment